title: Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).
abstract: Progestin preparations are made of synthetic progesterone and have often             been used for hormone therapy in gynecological patients with endometriosis or             endometrial cancer. Hormone therapy using progestin is considered to be one of             the effective means of treatment particularly when dealing with endometrial cancer             (an estrogen-dependent tumor). Numerous reports have been published concerning             its efficacy in advanced or recurrent cases of atypical endometrial hyperplasia             or endometrial cancer. Dienogest has been developed as a fourth-generation progestin             for hormone therapy for endometriosis that can be used with high safety for long             periods of time. In Japan, dienogest has been recommended as a first-line drug             for endometriosis-associated pain. However, its antitumor activity has also been             attracting close attention following a report that this drug suppressed the proliferation             in vitro of endometrial cancer-derived cell lines which failed to respond to other             progestins such as medroxyprogesterine acetate (MPA). The mechanism for antitumor             activity of dienogest is considered to differ from the mechanism for antitumor             activity of conventional progestin preparations used for treatment of endometrial             cancer. This drug is expected to be clinically applicable as a new drug for the             treatment of endometrial cancer.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan. kbanno@sc.itc.keio.ac.jp
authors.forename: Kouji
authors.initials: K
authors.lastname: Banno
authors.forename: Iori
authors.initials: I
authors.lastname: Kisu
authors.forename: Megumi
authors.initials: M
authors.lastname: Yanokura
authors.forename: Kosuke
authors.initials: K
authors.lastname: Tsuji
authors.forename: Kenta
authors.initials: K
authors.lastname: Masuda
authors.forename: Arisa
authors.initials: A
authors.lastname: Ueki
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Wataru
authors.initials: W
authors.lastname: Yamagami
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nomura
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Susumu
authors.forename: Daisuke
authors.initials: D
authors.lastname: Aoki
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011372:Progestins / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011372:Progestins; C023635:dienogest; D009277:Nandrolone